UBS Group
HRMY icon

UBS Group’s Harmony Biosciences HRMY Stock Holding History

UBS Group’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22M Buy
602,990
+154,999
+35% +$4.89M ﹤0.01% 2586
2026
Q1 		$12.5M Buy
447,991
+150,763
+51% +$4.94M ﹤0.01% 3109
2025
Q4 		$11.1M Sell
297,228
-205,853
-41% -$6.77M ﹤0.01% 3172
2025
Q3 		$13.9M Buy
503,081
+342,505
+213% +$11.8M ﹤0.01% 2952
2025
Q2 		$5.07M Sell
160,576
-21,949
-12% -$706K ﹤0.01% 3862
2025
Q1 		$6.06M Sell
182,525
-52,743
-22% -$1.89M ﹤0.01% 3589
2024
Q4 		$8.1M Buy
235,268
+139,375
+145% +$4.79M ﹤0.01% 3295
2024
Q3 		$3.84M Buy
95,893
+40,593
+73% +$1.43M ﹤0.01% 3354
2024
Q2 		$1.67M Sell
55,300
-58,177
-51% -$1.75M ﹤0.01% 3954
2024
Q1 		$3.81M Buy
113,477
+69,189
+156% +$2.22M ﹤0.01% 3262
2023
Q4 		$1.43M Buy
44,288
+28,965
+189% +$808K ﹤0.01% 4166
2023
Q3 		$502K Sell
15,323
-44,174
-74% -$1.53M ﹤0.01% 4649
2023
Q2 		$2.09M Buy
59,497
+39,503
+198% +$1.36M ﹤0.01% 3473
2023
Q1 		$653K Buy
19,994
+11,227
+128% +$511K ﹤0.01% 4486
2022
Q4 		$483K Buy
8,767
+8,401
+2,295% +$462K ﹤0.01% 4743
2022
Q3 		$16K Sell
366
-995
-73% -$48.5K ﹤0.01% 7685
2022
Q2 		$66K Sell
1,361
-9,470
-87% -$426K ﹤0.01% 5719
2022
Q1 		$527K Sell
10,831
-12,275
-53% -$501K ﹤0.01% 4650
2021
Q4 		$986K Buy
23,106
+4,968
+27% +$198K ﹤0.01% 4407
2021
Q3 		$695K Sell
18,138
-9,500
-34% -$306K ﹤0.01% 4492
2021
Q2 		$781K Buy
27,638
+20,496
+287% +$615K ﹤0.01% 4387
2021
Q1 		$236K Sell
7,142
-5,769
-45% -$202K ﹤0.01% 5363
2020
Q4 		$467K Sell
12,911
-9,089
-41% -$367K ﹤0.01% 4658
2020
Q3 		$746K Buy
+22,000
New +$802K ﹤0.01% 3859

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's HRMY Position: Q2 2026 in Review

UBS Group increased its Harmony Biosciences (HRMY) stake by 35% in Q2 2026, buying an estimated $4.89M and bringing the position to 602,990 shares worth $22M. The position accounts for ﹤0.01% of the portfolio, ranked #2586.

UBS Group first reported a position in HRMY in Q3 2020 and has held it in 24 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • UBS Group held 602,990 shares of Harmony Biosciences worth $22M as of Q2 2026.
  • UBS Group bought 154,999 Harmony Biosciences shares in Q2 2026, an estimated $4.89M.
  • Harmony Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2586 holding.
  • UBS Group first reported a position in Harmony Biosciences in Q3 2020 and has held it in 24 quarters since.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.